Lundbeck, Otsuka win EU nod for long-lasting Abilify; Aspen Pharmacare shares slide on GSK stake-sale news;

@FiercePharma: Wednesday's best-read story (still): Will Teva find a partner to save it from itself? More | Follow @FiercePharma

@EricPFierce: 350 sales folks get the ax as Actavis trims US force post Warner Chilcott merger. Story | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> The Danish pharma company Lundbeck and Japanese partner Otsuka won EU approval for their long-lasting version of the antipsychotic Abilify as a treatment for schizophrenia. Report

> A Madrid court ordered Germany-based Grünenthal, which made the morning sickness drug thalidomide now linked with birth defects, to pay at least €20,000 to each Spanish victim. Report

> Shares in South Africa's Aspen Pharmacare slid almost 4% on the news that GlaxoSmithKline ($GSK) had unloaded a third of its stake in the company. Report

> European austerity moves have cut into healthcare spending since the financial crisis of 2008, particularly in hard-hit markets such as Greece and Italy. Report (sub. req.)

> Johnson & Johnson ($JNJ) is fighting shareholder claims that it paid former CEO Bill Weldon too much. Report

> New research suggests that longtime users of birth control pills may be at higher risk of glaucoma. Report (sub. req.)

> JPMorgan raised its price target on Bayer to €112 from €100. Report

Medical Device News

@FierceMedDev: Medtronic scores promising results for next-gen stent graft. Story | Follow @FierceMedDev

@MarkHFierce: A Belgian company snagged some new funding for an interesting ophthalmic device, tech spun out of a Seattle outfit. Item | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More | Follow @MichaelGFierce

> Myriad partners up with BioMarin for cancer diagnostics. Article

> OraSure dumps Roche for Thermo Fisher in drug abuse Dx development deal. News

> Slumping Hologic downs poison pill as Icahn looms. Report

Biotech News

@FierceBiotech: FDA sets up roadblock for Forest, Richter, rejecting #schizophrenia drug. Story | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline politely dumps $230M Fabry drug deal with Amicus. News | Follow @JohnCFierce

@DamianFierce: Icahn buys into Hologic; Hologic swallows 10% poison pill. Release | Follow @DamianFierce

@EmilyMFierce: Imagining the Post-Antibiotics Future. Feature (via Medium) | Follow @EmilyMFierce

> Pfizer, GlaxoSmithKline forge cancer alliance in combo melanoma trial pact. More

> Flagship Ventures launches a biotech on the human microbiome sea. News

> Array slides as longtime CSO finds the exit. Item

Vaccines News

> European Union prepares to back vaccine stability project. News

> China's climate diversity creates flu vaccination complications. More

> WHO updates malaria roadmap with 2030 vaccine goals. Article

> U.S. gathers vaccine researchers to talk bioterrorism threat Q fever. Story

> CDC to import unapproved Novartis vaccine to stem Princeton meningitis outbreak. Piece

Pharma Manufacturing News

> JLL lines up financing for $2.6B Patheon, DSM deal. More

> GE Oslo plant gets FDA OK for new heart imaging product. News

> Pfizer to close Puerto Rico plant. Story

> Actavis puts California plant on hit list. Article

> Unilife grabs $40M contract to fill Hikma injectables. More

And Finally... Australian drugmaker CSL Ltd. is testing HDL cholesterol infusions as a way to stave off repeat heart attacks. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.